Healthcare Mergers, Acquisitions & Ventures Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Incyte Corporation
Drug discovery company announces filing of $175 million shelf registration
November 6th, 2004
Incyte Corporation (INCY) has filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC) for the proposed offering, from time to time, of up to $175 million of Incyte common stock. The company intends to use the proceeds from any offerings for general corporate purposes, which may include repayment or redemption of outstanding indebtedness and funding of clinical trials and drug discovery activities. Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company with a pipeline of oral compounds to treat HIV, inflammation, cancer, and diabetes. The company's...
Source: Healthcare Mergers, Acquisitions & Ventures Week (2004-11-06)
|
